Drugs / Yascarta
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06104592 Background | Nov 2023 → Dec 2026 expected | large B-cell lymphoma, non-Hodgkin lymphoma | H. Lee Moffitt Cancer Center and Research Institute | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Yascarta | “Yascarta is an autologous anti-CD19 CAR T cell therapy manufactured from the patient's own T cells, which have been extracted and then reprogrammed with CAR molecules to help...” NCT06104592 ↗ |
| Modality | Cell therapy | “anti-CD19 CAR T cell therapy” NCT06104592 ↗ |
| Target | CD19 | “anti-CD19 CAR T cell therapy” NCT06104592 ↗ |